Nephros (NASDAQ:NEPH) Receives “Speculative Buy” Rating from Benchmark

Nephros (NASDAQ:NEPH)‘s stock had its “speculative buy” rating reiterated by equities researchers at Benchmark in a report released on Tuesday,Benzinga reports. They currently have a $5.00 price objective on the stock. Benchmark’s price target indicates a potential upside of 210.56% from the stock’s previous close.

Nephros Stock Performance

Shares of NEPH stock opened at $1.61 on Tuesday. The stock has a market capitalization of $16.98 million, a price-to-earnings ratio of -17.89 and a beta of 1.19. Nephros has a one year low of $1.36 and a one year high of $4.04. The company’s 50-day simple moving average is $1.62 and its 200-day simple moving average is $1.94.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Nephros stock. Dimensional Fund Advisors LP purchased a new stake in shares of Nephros, Inc. (NASDAQ:NEPH) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 17,631 shares of the company’s stock, valued at approximately $37,000. Dimensional Fund Advisors LP owned 0.17% of Nephros as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 41.10% of the company’s stock.

Nephros Company Profile

Nephros, Inc, a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities.